ClinicalTrials.gg
WithdrawnNCT04348890Updated Sep 29, 2020

Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis

A Phase 1/2 interventional study of Vamorolone 4% suspension for oral dosing in Pediatric Ulcerative Colitis, sponsored by ReveraGen BioPharma, Inc.. Withdrawn. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-09-29.

Sponsored by ReveraGen BioPharma, Inc. · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
Programmatic decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
4 Years to 17 Years
Sex
All
01

Study summary

This is a Phase I/II, multi-center, open-label proof-of-concept study of vamorolone. Twenty participants with a flare of mild or moderately active Ulcerative Colitis (defined as a Pediatric Ulcerative Colitis Activity Index [PUCAI] 10-60) will be enrolled and receive vamorolone 6 mg/kg/day orally once daily for 8 weeks.

02

Conditions studied

  • Pediatric Ulcerative Colitis
03

In context

Lead sponsor

ReveraGen BioPharma, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided written /Health Insurance Portability and Accountability Act (HIPAA) authorization prior to any study-related procedures;
  • Subject has current mild to moderately active ulcerative colitis, defined as a PUCAI score of 10-60.
  • Subject is ≥ 4 years old and \<18 years old at the time of enrollment.
  • Subject has had 1) a colonoscopy demonstrating endoscopic and histologic inflammation, and/or; 2) a fecal calprotectin > 250 mcg/g, in the preceding 1 month.
  • Subject is willing and able to comply with scheduled visits, study drug administration plan, and study procedures.
  • Subject has not started a new immunomodulator or biologic in the preceding 2 months.
  • If subject is taking an immunomodulator and/or biologic, the dose has not been changed in the last 2 months
  • Subject has a positive varicella IgG titer, or history of at least 2 documented varicella vaccines

Exclusion criteria

Exclusion Criteria:

  • Subject is currently being treated or has received previous treatment with oral or rectal (including budesonide) in the past month
  • Subject has an allergy or to the study medication or to any of its constituents
  • Subject has previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow-up will be correctly completed or impair the assessment of study results, in the opinion of the Investigator
  • Subject is taking any other drug currently or has taken any other investigational drug within 3 months prior to the start of study treatment
  • abnormal biochemical and hematological parameters, including:

    • \< 1000 cells/mm3
    • count ≤ 130 cells/mm3
    • Creatinine ≥ 1.2 x the
    • (ALT) and/or aspartate aminotransferase (AST) ≥ 2x the upper limit of normal
    • Conjugated greater than 1.2. mg/dL
  • Has active infection with enteric pathogens (including C. difficile)
  • Has a positive PPD, Quantiferon Gold, or Interferon-gamma assay
  • Is pregnant or breast-feeding
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    Drug: Vamorolone 4% suspension for oral dosing

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Remission

    Pediatric Ulcerative Colitis Activity Index score \<10 and no additional therapy or colectomy). The PUCAI is scored from 0-85, lower numbers indicate less severe disease activity.

    Time frame: 8 weeks

Secondary outcomes

  1. Safety (adverse events)

    Time frame: From day 1 through 30 days after last dose

  2. Change in osteocalcin, P1NP, CTX

    Bone biomarkers

    Time frame: From baseline to week 8 and week 12

  3. Cushingoid appearance

    Physician reported, yes or no

    Time frame: Week 8 and Week 12

  4. Week 8 response

    Decrease in PUCAI score by 20 points or more (lower scores indicate less severe disease activity)

    Time frame: Baseline to 8 Weeks and 12 Weeks

  5. Change in Mayo Score Stool Frequency subscore

    Score ranges from 0-3, with lower scores indicating less severe disease activity

    Time frame: Baseline to 8 Weeks and 12 Weeks

  6. Change in Mayo rectal bleeding score

    Scores range from 0-3, with lower scores indicating less severe disease activity

    Time frame: Baseline to 8 Weeks and 12 Weeks

  7. Mayo Score Stool Frequency subscore of 0 or 1

    Time frame: Week 12

  8. Mayo Score Rectal Bleeding Score of 0

    Time frame: Week 12

  9. Change in fecal calprotectin

    Time frame: Baseline to Week 8 and Week 12

  10. Change in serum C-reactive protein

    Time frame: Baseline to Week 8 and Week 12

  11. Change in serum CCL22

    Time frame: Baseline to Week 8 and Week 12

  12. Change in serum miRNA 146b

    Time frame: Baseline to Week 8 and Week 12

  13. Change in serum trefoil factor 3

    Time frame: Baseline to Week 8 and Week 12

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2020; primary completion for Sep 2022, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2020
First posted
Apr 16, 2020
StartEst.
Sep 1, 2020
Primary completionEst.
Sep 1, 2022
CompletionEst.
Sep 1, 2022
Last update
Sep 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04348890
Lead sponsor
ReveraGen BioPharma, Inc.
Responsible party
Sponsor
First posted
Apr 16, 2020
Start date
Sep 1, 2020 (estimated)
Primary completion
Sep 1, 2022 (estimated)
Completion
Sep 1, 2022 (estimated)
Last update
Sep 29, 2020

Study contacts

Laurie Conklin, MD
study director · ReveraGen BioPharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vamorolone

Start the discussion